Poststroke Depression, An Underrated Clinical Dilemma: 2022

• Published in: Curēus (Palo Alto, CA) Vol. 14; no. 12; p. e32948
• Main Authors: Jamil, Aneeque, Csendes, Denise, Gutlapalli, Sai Dheeraj, Prakash, Keerthana, Swarnakari, Kiran Maee, Bai, Meena, Manoharan, Mohana Priya, Raja, Rabab, Desai, Aditya, Desai, Darshi M, Arcia Franchini, Ana P
• Format: Journal Article
• Language: English
• Published: United States Cureus Inc 26.12.2022
• Subjects: Etiology; Hormones; Magnetic resonance imaging; Mental depression; Pathophysiology; Stroke; Suicidal behavior; Suicides & suicide attempts; stroke and psychiatry; depression; stroke; stroke and mental health; poststroke depression
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.32948

It is known that the majority of patients are prone to develop depression following a stroke. Several biological factors, including the disruption of the hypothalamic and adrenal axis and changes in cortisol and interleukin 6 (IL6), are said to have an essential role in its development. Magnetic resonance imaging (MRI) scans point toward white matter lesions and lacunar infarcts as the primary pathological culprit. People affected by poststroke depression (PSD) are more likely to commit suicide or develop another ischemic event after the initial episode, which can likely increase the mortality related to PSD and stroke. Selective serotonin reuptake inhibitors (SSRIs) are the mainstay of treatment for PSD. However, it has a poor safety profile and is not very productive, making the use of SSRIs controversial, and further studies are required to prove its benefits concerning PSD. This literature review discusses the importance of PSD, how it impacts the quality of life of people affected by stroke, and its treatment.